Commercial Insight - CNS Market Overview - Commercial Dynamics and Outlook of the Neurology, Pain and Psychiatry Market Sectors
The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007.
Northampton, United Kingdom, May 27, 2008 --(PR.com)-- http://www.companiesandmarkets.com adds new report - Commercial Insight - CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors.
http://www.companiesandmarkets.com/Summary-Market-Report/Commercial-Insight-CNS-Market-Overview-
Commercial-dynamics-and-outlook-of-the-neurology,-pain-and-psychiatry-market-sectors-30341.asp
The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer.
Scope
An inter and intra-sector view of the CNS market and its key components-neurology, pain, and psychiatry-in Japan, the US, and 5EU
Market size, structure, key brands, and company prescription sales value and volume data analyzed in each sector
Top-line analysis of key indications in each sector, drawing on key insights with disease-specific market trends and forecasts
Assessment of the commercial viability of the future CNS market with strategic recommendations to aid R&D decisions
Highlights
When comparing the three CNS sectors the pain sector is by far the largest by volume prescriptions, accounting for 53.5% of the 2007 CNS market total. However, in terms of value, psychiatry is the dominant sector, accounting for over 48% of total CNS sales, whereas neurology is the fastest growing sector.
On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer's disease offers the greatest commercial opportunity for pharmaceutical companies in neurology.
Currently dominated by Big Pharma players and a number of multi-blockbuster antidepressant and antipsychotic brands, the psychiatry market value will begin to decrease from 2010 onwards as key patents begin to expire. Nevertheless, continued investment will eventually see the R&D pipeline yield new improved agents with blockbuster potential.
Reasons to Purchase
Identify the commercial and clinical characteristics for the major CNS markets across Japan, the US and M5EU.
Understand the future market landscape to align R&D decisions and target the indications that offer the most opportunity to your company.
Quantify the key historical company and brand dynamics that have shaped the three CNS market sectors.
http://www.companiesandmarkets.com/Summary-Market-Report/Commercial-Insight-CNS-Market-Overview-
Commercial-dynamics-and-outlook-of-the-neurology,-pain-and-psychiatry-market-sectors-30341.asp
###
http://www.companiesandmarkets.com/Summary-Market-Report/Commercial-Insight-CNS-Market-Overview-
Commercial-dynamics-and-outlook-of-the-neurology,-pain-and-psychiatry-market-sectors-30341.asp
The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer.
Scope
An inter and intra-sector view of the CNS market and its key components-neurology, pain, and psychiatry-in Japan, the US, and 5EU
Market size, structure, key brands, and company prescription sales value and volume data analyzed in each sector
Top-line analysis of key indications in each sector, drawing on key insights with disease-specific market trends and forecasts
Assessment of the commercial viability of the future CNS market with strategic recommendations to aid R&D decisions
Highlights
When comparing the three CNS sectors the pain sector is by far the largest by volume prescriptions, accounting for 53.5% of the 2007 CNS market total. However, in terms of value, psychiatry is the dominant sector, accounting for over 48% of total CNS sales, whereas neurology is the fastest growing sector.
On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer's disease offers the greatest commercial opportunity for pharmaceutical companies in neurology.
Currently dominated by Big Pharma players and a number of multi-blockbuster antidepressant and antipsychotic brands, the psychiatry market value will begin to decrease from 2010 onwards as key patents begin to expire. Nevertheless, continued investment will eventually see the R&D pipeline yield new improved agents with blockbuster potential.
Reasons to Purchase
Identify the commercial and clinical characteristics for the major CNS markets across Japan, the US and M5EU.
Understand the future market landscape to align R&D decisions and target the indications that offer the most opportunity to your company.
Quantify the key historical company and brand dynamics that have shaped the three CNS market sectors.
http://www.companiesandmarkets.com/Summary-Market-Report/Commercial-Insight-CNS-Market-Overview-
Commercial-dynamics-and-outlook-of-the-neurology,-pain-and-psychiatry-market-sectors-30341.asp
###
Contact
companiesandmarkets.com
Mike King
+44 (0) 1933674780
www.companiesandmarkets.com
Mike King
+44 (0) 1933674780
www.companiesandmarkets.com
Contact
Categories